Tyrosine kinase inhibitor and uses thereof

A compound of Formula (I), or a pharmaceutically acceptable salt, ester, or stereoisomer thereof:

• wherein
• Z1 is N;
• Z2 is N;
• X is NR5 or absent;
• Y is NR5;
• Ring A is phenyl optionally substituted by a substituent, wherein the substituent is selected from hydrogen atom, halogen atom, cyano, C1-4alkyl, C1-4alkoxy or halo-C1-4alkyl;
• Ring B is phenyl optionally substituted by a substituent, wherein the substituent is hydrogen atom, halogen atom, cyano, C1-4alkyl, C1-4alkoxy, halo-C1-4alkyl, halo-C1-4alkoxy, C1-4alkylsulfonyl, C1-4alkylsulfonyloxy, or C1-4alkylsulfonylC1-4alkoxy;
• Ring C is 7-10 membered N-containing fused heterocyclyl, 7-9 membered spiroheterocyclyl or 8 membered bridged heterocyclyl, each of which is optionally substituted by a substituent, wherein the substituent is hydrogen atom, halogen atom, cyano, C1-4alkyl, C1-4alkoxy, halo-C1-4alkyl, halo-C1-4alkoxy, C1-4alkylsulfonyl, C1-4alkylsulfonyloxy, C1-4alkylsulfonylC1-4alkoxy or 3-6 membered O-containing heterocyclyl;
• or Ring C is 5-6 membered N-containing heterocyclyl which is substituted by 3-6 membered O-containing heterocyclyl, and when Ring A is phenyl and Ring B is phenyl, Ring C is not piperazinyl or morpholinyl;
• R1 is selected from halo-methyl or halo-ethyl;
• R2 is selected from hydrogen atom, —N(R6)(R7), —N(R6)C(O)(R7), C1-4alkyl or 3-6 membered cycloalkyl;
• R3 is hydrogen atom;
• or R3 is C1-4alkyl, C1-4alkoxy or —C(O)—R8, each of which is optionally substituted by a substituent, wherein the substituent is selected from hydrogen atom, halogen atom or C1-4alkyl or C1-4alkylsulfonyl;
• R5 is selected from hydrogen atom, halogen atom or C1-4alkyl;
• R6 and R7 are independently selected from hydrogen atom, C1-4alkyl, halo-C1-4alkyl or C2-4alkenyl;
• R8 is selected from hydrogen atom, methyl, ethyl or methoxyl.